FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1995857462> ?p ?o ?g. }

• W1995857462 endingPage "E45" @default.
• W1995857462 startingPage "E40" @default.
• W1995857462 abstract "Dabigatran is an oral direct thrombin inhibitor recently approved for stroke prevention in atrial fibrillation (AF) as an alternative to warfarin. The primary advantages of dabigatran are freedom from monitoring and less interaction with other drugs and food. It is ideal for patients who are unwilling to adhere to regular coagulation monitoring or whose therapeutic effect using warfarin is not optimal despite adequate monitoring and management. However, the impact of dabigatran on health-related quality of life (HRQoL) and drug compliance has been less evaluated. This study aimed to evaluate the clinical and humanistic outcomes of dabigatran use in Hong Kong.Dabigatran 110 mg twice daily was non-inferior in stroke prophylaxis in AF patients compared to adjusted-dose warfarin; while dabigatran 150 mg twice daily was superior to adjusted-dose warfarin in the real world data in Hong Kong.We retrospectively analyzed 244 patients with newly diagnosed AF and prescribed dabigatran (n = 122) or warfarin (n = 122) for stroke prophylaxis from the Prince of Wales Hospital between January 2010 to November 2011. Clinical outcomes including death, stroke, bleeding, and HRQoL using the EuroQol EQ-5D-5L were compared between patients on dabigatran and warfarin.The median duration of follow-up was 310 days. Stroke occurred in 2 patients (1.64%) in the dabigatran group and 4 in the warfarin group (3.28%) (adjusted hazard ratio [HR]: 0.53, P = 0.47). Bleeding of any degree occurred in 28 patients on dabigatran and 38 patients on warfarin (adjusted HR: 0.76, P = 0.28), with age over 70 years and renal impairment being significant positive predictors of bleeding (P = 0.01 and 0.02, respectively). Dyspepsia was the most common adverse event of dabigatran over warfarin (19.7% vs 8.2%, P = 0.01). Rate of discontinuation of dabigatran was 25.4%, with dyspepsia being the most common cause for discontinuation (6 patients, 4.92%). There was no significant difference in drug compliance or HRQoL at 1 year between the 2 groups (utility score 0.77 [dabigatran] vs 0.74 [warfarin], P = 0.28).In Hong Kong, the clinical efficacy and safety of dabigatran were comparable to that of warfarin, and drug compliance and HRQoL of using dabigatran and warfarin were similar after 1 year of use." @default.
• W1995857462 created "2016-06-24" @default.
• W1995857462 creator A5046210822 @default.
• W1995857462 creator A5053589377 @default.
• W1995857462 creator A5056364607 @default.
• W1995857462 creator A5064715130 @default.
• W1995857462 creator A5069810420 @default.
• W1995857462 creator A5078874687 @default.
• W1995857462 date "2012-10-25" @default.
• W1995857462 modified "2023-09-27" @default.
• W1995857462 title "Dabigatran Compared With Warfarin for Stroke Prevention With Atrial Fibrillation: Experience in Hong Kong" @default.
• W1995857462 cites W1506966900 @default.
• W1995857462 cites W1966242613 @default.
• W1995857462 cites W1999468381 @default.
• W1995857462 cites W2050306424 @default.
• W1995857462 cites W2052478023 @default.
• W1995857462 cites W2060630424 @default.
• W1995857462 cites W2078103904 @default.
• W1995857462 cites W2081205482 @default.
• W1995857462 cites W2114775432 @default.
• W1995857462 cites W2132727148 @default.
• W1995857462 cites W2153196285 @default.
• W1995857462 cites W2162586165 @default.
• W1995857462 cites W2164861810 @default.
• W1995857462 cites W2989714602 @default.
• W1995857462 cites W4292280632 @default.
• W1995857462 doi "https://doi.org/10.1002/clc.22069" @default.
• W1995857462 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6652425" @default.
• W1995857462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23108916" @default.
• W1995857462 hasPublicationYear "2012" @default.
• W1995857462 type Work @default.
• W1995857462 sameAs 1995857462 @default.
• W1995857462 citedByCount "34" @default.
• W1995857462 countsByYear W19958574622013 @default.
• W1995857462 countsByYear W19958574622014 @default.
• W1995857462 countsByYear W19958574622015 @default.
• W1995857462 countsByYear W19958574622016 @default.
• W1995857462 countsByYear W19958574622017 @default.
• W1995857462 countsByYear W19958574622018 @default.
• W1995857462 countsByYear W19958574622019 @default.
• W1995857462 countsByYear W19958574622020 @default.
• W1995857462 countsByYear W19958574622021 @default.
• W1995857462 countsByYear W19958574622023 @default.
• W1995857462 crossrefType "journal-article" @default.
• W1995857462 hasAuthorship W1995857462A5046210822 @default.
• W1995857462 hasAuthorship W1995857462A5053589377 @default.
• W1995857462 hasAuthorship W1995857462A5056364607 @default.
• W1995857462 hasAuthorship W1995857462A5064715130 @default.
• W1995857462 hasAuthorship W1995857462A5069810420 @default.
• W1995857462 hasAuthorship W1995857462A5078874687 @default.
• W1995857462 hasBestOaLocation W19958574621 @default.
• W1995857462 hasConcept C126322002 @default.
• W1995857462 hasConcept C127413603 @default.
• W1995857462 hasConcept C177713679 @default.
• W1995857462 hasConcept C2776301958 @default.
• W1995857462 hasConcept C2776710957 @default.
• W1995857462 hasConcept C2778810321 @default.
• W1995857462 hasConcept C2779161974 @default.
• W1995857462 hasConcept C2780645631 @default.
• W1995857462 hasConcept C42219234 @default.
• W1995857462 hasConcept C71924100 @default.
• W1995857462 hasConcept C78519656 @default.
• W1995857462 hasConceptScore W1995857462C126322002 @default.
• W1995857462 hasConceptScore W1995857462C127413603 @default.
• W1995857462 hasConceptScore W1995857462C177713679 @default.
• W1995857462 hasConceptScore W1995857462C2776301958 @default.
• W1995857462 hasConceptScore W1995857462C2776710957 @default.
• W1995857462 hasConceptScore W1995857462C2778810321 @default.
• W1995857462 hasConceptScore W1995857462C2779161974 @default.
• W1995857462 hasConceptScore W1995857462C2780645631 @default.
• W1995857462 hasConceptScore W1995857462C42219234 @default.
• W1995857462 hasConceptScore W1995857462C71924100 @default.
• W1995857462 hasConceptScore W1995857462C78519656 @default.
• W1995857462 hasIssue "12" @default.
• W1995857462 hasLocation W19958574621 @default.
• W1995857462 hasLocation W19958574622 @default.
• W1995857462 hasLocation W19958574623 @default.
• W1995857462 hasLocation W19958574624 @default.
• W1995857462 hasOpenAccess W1995857462 @default.
• W1995857462 hasPrimaryLocation W19958574621 @default.
• W1995857462 hasRelatedWork W1973989324 @default.
• W1995857462 hasRelatedWork W1993190469 @default.
• W1995857462 hasRelatedWork W2018572947 @default.
• W1995857462 hasRelatedWork W2022043463 @default.
• W1995857462 hasRelatedWork W2080910965 @default.
• W1995857462 hasRelatedWork W2090821460 @default.
• W1995857462 hasRelatedWork W2097201002 @default.
• W1995857462 hasRelatedWork W2108977729 @default.
• W1995857462 hasRelatedWork W2170786340 @default.
• W1995857462 hasRelatedWork W1810372846 @default.
• W1995857462 hasVolume "35" @default.
• W1995857462 isParatext "false" @default.
• W1995857462 isRetracted "false" @default.
• W1995857462 magId "1995857462" @default.
• W1995857462 workType "article" @default.